Immunosuppressant Peptide Abu-TGIRIS-Abu-NH2 and its Application for Treatment of Multiple Sclerosis.

Abstract

Immunosuppressant peptide immunocortin for the first time was described in 1993. It corresponds to residues 11-20 of human Ig heavy chain (conserved motif of VH domain). There are no data about production of immunocortin by proteolysis of Ig in vivo. Synthetic immunocortin in concentration ~ 10-9 M suppresses phagocytosis in peritoneal macrophages, ConA-dependent blast transformation of rat lymphocytes, exhibits ACTH-like neurotropic activity and was suggested as a potential drug for treatment of a multiple sclerosis (MS). Here, we report a sequence and method of synthesis of Abu-TGIRIS-Abu-NH2 (Abu, alpha-aminobutyric acid), an artificial analogue of immunocortin. Biological trials of peritoneally injected Abu-TGIRIS-Abu-NH2 gave an evidence of its better efficacy versus immunocortin in a test for suppression of the experimental autoimmune encephalomyelitis (EAE) in Dark Agouti (DA) rats.

• Authors: Valery I Turobov, Viatcheslav N Azev, Alexei B Shevelev, Natalia V Pozdniakova, Yulia K Biryukova, Arkady N Murashev, Valery M Lipkin, Igor P Udovichenko
• Journal: BioNanoScience (Bionanoscience) Vol. 8 Issue 1 Pg. 484-489 ( 2018) ISSN: 2191-1630 [Print] United States
• PMID: 29600159 (Publication Type: Journal Article)